Atossa To Conduct Endoxifen Mid-Stage Study In Sweden

by Vandana Singh, Benzinga Editor

September 2, 2021 11:00 AM | 1 min read |

Atossa Therapeutics Inc ATOS has received approval from the Swedish Ethics Review Authority to begin a Phase 2 clinical study of oral Endoxifen to reduce mammographic breast density (MBD).
Atossa plans to start enrolling participants in Q4 of 2021.
The Karisma-Endoxifen study will enroll 240 healthy premenopausal women with increased breast density.
The study's primary objective is to determine the dose-response relationship of daily oral Endoxifen on MBD reduction.
Secondary endpoints for the trial include safety and tolerability.
The trial will be conducted in Stockholm, and participants will receive daily doses of oral Endoxifen or placebo for six months.
Price Action: ATOS stock is up 2.62% at $3.85 during the market session on the last check Thursday.

Posted In:

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.